Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common diabetes pill save transplanted kidneys?

NCT ID NCT07555106

First seen May 07, 2026 · Last updated May 19, 2026 · Updated 3 times

Summary

This study tests whether dapagliflozin, a drug used for diabetes, can help protect kidney function in people who received a kidney transplant from a living donor. About 54 adults will take the drug daily or receive standard care. Researchers will measure kidney function, scarring, and rejection over 12 months to see if the drug improves outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Universidad de Guadalajara

    Guadalajara, Jalisco, 44250, Mexico

Conditions

Explore the condition pages connected to this study.